Gemphire Therapeutics (GEMP) is Initiated by RBC Capital Mkts to Outperform, Price Target at $25

Gemphire Therapeutics (GEMP) was Initiated by RBC Capital Mkts to “Outperform” and the brokerage firm has set the Price Target at $25. RBC Capital Mkts advised their investors in a research report released on Aug 30, 2016.

Gemphire Therapeutics

Leave a Reply

Gemphire Therapeutics - Is it time to Sell?

Top Brokerage Firms are advising their investors on Gemphire Therapeutics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.